The National Cancer Institute aims to lessen the burden of cancer through scientific evidence. In 2016, there will be an estimated 1.7 million new cancer cases and 600,000 cancer deaths in the United States. Precision medicine will lead to a fundamental understanding of the complex interplay between genetics, epigenetics, nutrition, environment and clinical presentation to direct effective cancer prevention and treatment. The Cancer Moonshot initiative utilizes precision medicine, national computing initiatives, and making genomic data widely available to investigate and explore cancer prediction using real-world data.
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
Nci clinical genomics data sharing ncra sept 2016Warren Kibbe
Gave an update on the Cancer Research Data Ecosystem, the Genomic Data Commons, Cloud Pilots, incentives for data sharing in cancer research to the NCI Council of Research Advocates (NCRA) on Monday, September 26th, 2016
Converged IT Summit - NCI Data SharingWarren Kibbe
Cancer Moonshot, Data Sharing, Genomic Data Commons, NCI Cloud Pilots, Cancer Research Data Ecosystem, technology advances, chemotherapy advances, MATCH, NCI Cancer Moonshot Blue Ribbon Panel Recommendations
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
Nci clinical genomics data sharing ncra sept 2016Warren Kibbe
Gave an update on the Cancer Research Data Ecosystem, the Genomic Data Commons, Cloud Pilots, incentives for data sharing in cancer research to the NCI Council of Research Advocates (NCRA) on Monday, September 26th, 2016
Converged IT Summit - NCI Data SharingWarren Kibbe
Cancer Moonshot, Data Sharing, Genomic Data Commons, NCI Cloud Pilots, Cancer Research Data Ecosystem, technology advances, chemotherapy advances, MATCH, NCI Cancer Moonshot Blue Ribbon Panel Recommendations
NCI Cancer Genomics, Open Science and PMI: FAIR Warren Kibbe
Talk given to the NLM Fellows on July 8, 2016. Touches on Cancer Genomics, Open Science and PMI: FAIR in NCI genomics thinking and projects. Includes discussion of the Genomic Data Commons (GDC), Cancer Data Ecosystem, Data sharing, and the NCI cancer clinical trials open API.
NCI Cancer Imaging Program - Cancer Research Data EcosystemWarren Kibbe
Given to the NCI Cancer Imaging Program monthly telecon on January 9th, 2017. NCI Genomic Data Commons, Beau Biden Cancer Moonshot Blue Ribbon Panel, Cancer Research Data Ecosystem and the role of imaging in precision medicine
FDA NGS and Big Data Conference September 2014Warren Kibbe
Presentation for the FDA NGS and Big Data Conference September 2014 held on the NIH campus. NCI initiatives, including Cancer Genomics Data Commons, NCI Cloud Pilots, big data issues for cancer
CI4CC Moonshot Blue Ribbon Panel Report 20161010Warren Kibbe
Presentation to the Fall CI4CC meeting in Utah. CI4CC Moonshot Blue Ribbon Panel Report. Highlights of Vice President Biden's Cancer Moonshot and the NCI Blue Ribbon Panel Recommendations.
DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com...Warren Kibbe
May 2016 FNLAC presentation of the DOE-NCI partnership around three pilots focused on existing projects in NCI and existing NSCI directives and activities in DOE.
2016 Data Commons and Data Science Workshop June 7th and June 8th 2016. Genomic Data Commons, FAIR, NCI and making data more findable, publicly accessible, interoperable (machine readable), reusable and support recognition and attribution
May 2016 NCI Cancer Center Directors meeting. Data Sharing and the Cancer Genomic Data Commons (GDC). Focus is on cancer genomic and clinical phenotype data.
SILS 2015 - Connecting Precision Medicine to Precision Wellness Sherbrooke Innopole
By: Joel Dudley, Mount Sinai School of Medicine
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
Drinking excessive alcohol can contribute to the risk of developing breast cancer. Alcohol contains a lot of calories that can lead to excess weight, which in turn can increase our risk of breast cancer.
NCI Cancer Genomics, Open Science and PMI: FAIR Warren Kibbe
Talk given to the NLM Fellows on July 8, 2016. Touches on Cancer Genomics, Open Science and PMI: FAIR in NCI genomics thinking and projects. Includes discussion of the Genomic Data Commons (GDC), Cancer Data Ecosystem, Data sharing, and the NCI cancer clinical trials open API.
NCI Cancer Imaging Program - Cancer Research Data EcosystemWarren Kibbe
Given to the NCI Cancer Imaging Program monthly telecon on January 9th, 2017. NCI Genomic Data Commons, Beau Biden Cancer Moonshot Blue Ribbon Panel, Cancer Research Data Ecosystem and the role of imaging in precision medicine
FDA NGS and Big Data Conference September 2014Warren Kibbe
Presentation for the FDA NGS and Big Data Conference September 2014 held on the NIH campus. NCI initiatives, including Cancer Genomics Data Commons, NCI Cloud Pilots, big data issues for cancer
CI4CC Moonshot Blue Ribbon Panel Report 20161010Warren Kibbe
Presentation to the Fall CI4CC meeting in Utah. CI4CC Moonshot Blue Ribbon Panel Report. Highlights of Vice President Biden's Cancer Moonshot and the NCI Blue Ribbon Panel Recommendations.
DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com...Warren Kibbe
May 2016 FNLAC presentation of the DOE-NCI partnership around three pilots focused on existing projects in NCI and existing NSCI directives and activities in DOE.
2016 Data Commons and Data Science Workshop June 7th and June 8th 2016. Genomic Data Commons, FAIR, NCI and making data more findable, publicly accessible, interoperable (machine readable), reusable and support recognition and attribution
May 2016 NCI Cancer Center Directors meeting. Data Sharing and the Cancer Genomic Data Commons (GDC). Focus is on cancer genomic and clinical phenotype data.
SILS 2015 - Connecting Precision Medicine to Precision Wellness Sherbrooke Innopole
By: Joel Dudley, Mount Sinai School of Medicine
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
Drinking excessive alcohol can contribute to the risk of developing breast cancer. Alcohol contains a lot of calories that can lead to excess weight, which in turn can increase our risk of breast cancer.
Elsevier Medical Graph – mit Machine Learning zu Precision MedicineRising Media Ltd.
Elsevier Health Analytics entwickelt den Medical Knowledge Graph, welcher Korrelationen zwischen Krankheiten und zwischen Krankheiten und Behandlungen darstellt. Auf einem Gesamtdatensatz von sechs Millionen anonymisierten Patienten, beobachtbar über sechs Jahre, haben wir über 2000 Modelle erstellt, welche die Entwicklung von Krankheiten prognostizieren. Jedes Modell ist adjustiert für mehr als 3000 Kovariablen. Dazu kam ein Boosting Algorithmus mit Variablenselektion zum Einsatz. Die Betas der selektierten Variablen wurden extrahiert, getestet hinsichtlich Kausalität und Signifikanz, und daraus wurde die erste Version des Medical Graphen mit über 2000 Krankheitsknoten und 25.000 Effekt-Kanten gebaut. Der Graph wird aktuell in der Praxis getestet, mit dem Ziel, dem Arzt eine patienten-individuelle Entscheidungsunterstützung für die Behandlung zu geben.
Genomic Medicine: Personalized Care for Just PenniesHealth Catalyst
In April 2003, the Human Genome Project was completed and scientists gained the ability to read the entire genetic blueprint for human beings. Since that time, the cost of gene sequencing has fallen from $100 million to $1,000. By 2020, the cost is expected to be mere pennies. Using the power of genomes scientists have found genomic defects for more than 5,000 inherited diseases and are on track to uncover 4,000 more. The implications for treatment of disease are also vast. In the future, clinicians will be able to use genomic-powered personalized medicine to treat patients on an individual basis knowing exactly how their genes will react to treatments and what the best course of action will be.
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
3 Things Every Sales Team Needs to Be Thinking About in 2017Drift
Thinking about your sales team's goals for 2017? Drift's VP of Sales shares 3 things you can do to improve conversion rates and drive more revenue.
Read the full story on the Drift blog here: http://blog.drift.com/sales-team-tips
Summary: At The Economist’s War on Cancer 2015 event on 20 October 2015 (http://www.economist.com/events-conferences/emea/war-cancer-london), EY’s Silvia Ondategui-Parra joined the panel discussion “The patient/payer debate—balancing clinical need and affordability.” The panel explored the ongoing tension between the soaring cost of cancer drugs and governments’ ability to fund them and raised the question, do we need an entirely new pricing model? This EY infographic was developed to highlight some of the key trends driving the debate.
Hugh Mason gave this keynote presentation at the Media Exploits 2015, SE Asia's largest Infocomm Media Technology commercialisation showcase and networking event, held in Singapore. Seismic macro-level trends are disrupting the healthcare industry, opening up new opportunities for innovation. Lean Startup is one of a range of tools and approaches that help to provide a patient-centred approach to making sense and making money in the new landscape.
How do we see the healthcare's digital future and its impact on our lives?Jane Vita
"Healthcare is undergoing major changes spurred on by, but not limited to, technology.
Digitalisation is changing the way we think about health, what taking care of it really entails, our personal role in healthcare systems and the way we interact with technology in the context of health.
In many ways, we are entering a post-institutional age of increased personal responsibility, which presents healthcare service providers and other players in the field with major opportunities and great risks. Technology has the potential to empower people and help them become more active in the management of their and their families’ health. This will change the relationship of the patient and the caregiver in profound ways." Mirkka Länsisalo
A co-creation with Mirkka Läansisalo and Sala Heinänen, at Futurice.
Evaluation of comorbid autoimmune diseases among patients and family members enrolled in the Alopecia
Areata Registry, Biobank & Clinical Trials Network.
Keynote at NVIDIA GPU Technology Conference in D.C.Jerry Lee
Presentation at NVIDIA GPU Technology Conference in D.C. on how the Cancer Moonshot Task Force under Vice President Biden is using AI to help end cancer as we know it. Dr. Lee will discuss global efforts to empower A.I. and deep learning for oncology with larger and more accessible datasets.
From Discovery to Delivery: Benchwork to Global Health: Corey CasperUWGlobalHealth
Explores relationships and discrepancies between important research-based medical advancements and subsequent real world implementation. Advancements in the management and potential elimination of infectious diseases such as HIV and TB will be addressed, as related to development and implementation of effective diagnostics, vaccines, or treatments.
US Federal Cancer Moonshot- One Year LaterJerry Lee
Presentation from former Cancer Moonshot Data and Technology Track Co-chairs Jerry S.H. Lee, PhD (NCI, former OVP) and Dimitri Kusnezov, PhD (DOE) to update on efforts that will help realize the Data/Tech Track's vision of a national learning healthcare system for cancer. These include NCI/DOE pilots, DOE/VA pilot, NCI GDC, DoD/VA/NCI APOLLO, NCI/GSK ATOM, and BloodPAC.
VOLUME 22, NUMBER 1 CLINICAL JOURNAL OF ONCOLOGY NURSING 69CJO.docxjessiehampson
VOLUME 22, NUMBER 1 CLINICAL JOURNAL OF ONCOLOGY NURSING 69CJON.ONS.ORG
C
Colorectal Cancer
A collaborative approach to improve education and screening
in a rural population
Marsha Woodall, DNP, MBA, RN, and Mary DeLetter, PhD, RN
COLORECTAL CANCER (CRC) INCLUDES ANY CANCER THAT starts in the colon or
rectum. Most begin as an adenomatous polyp and grow into the wall of the
colon or rectum before metastasizing by invading tissues or structures, the
bloodstream, or the lymphatic system. About 95% of CRCs are adenocarci-
nomas (American Cancer Society [ACS], 2017b). The ACS (2017a) projected
that 135,430 people would be diagnosed with CRC in the United States in
2017. Although the CRC death rate has been dropping for the past 20 years,
the ACS still estimated 50,260 CRC-related deaths during 2017 (ACS, 2017a).
The Centers for Disease Control and Prevention ([CDC], 2017) recom-
mends screening for precancerous polyps for anyone aged 50 years or older.
Although early detection and diagnosis greatly affect survival rates, only about
half of the U.S. population participates in screening (ACS, 2017a). A fecal
immunochemical test (FIT) is a noninvasive test used to detect blood in the
stool that cannot be seen with the human eye (Tresca, 2017). People at home
use the FIT kit by obtaining a sample of the stool with one of the FIT kit sticks
and inserting the sample back in the vial. The FIT kits are then either mailed or
hand-delivered to a laboratory for blood detection, most specifically from the
lower gastrointestinal tract (Tresca, 2017).
The State Cancer Profiles report by the National Cancer Institute (NCI)
and CDC (2014) ranked Kentucky seventh for mortality, with a death rate
of 17.6 per 100,000 compared to a national rate of 15.1. At the time of this
project, the CRC death rate in Hopkins County, Kentucky, was 14.1 per
100,000, one of the highest in the state. The death rate in Kentucky has been
trending downward over time from 25.8 in 1982 to 17.6 in 2013 (NCI and CDC,
2014). Incidence and death rates are depicted in Figure 1.
In 2008, the Kentucky Colon Cancer Screening Program (KCCSP) was
formed with the passage of Kentucky Regulatory Statute 214.540 to increase
CRC screening, reduce morbidity and mortality from CRC, and reduce costs
for CRC treatment. The goal of the KCCSP is to increase the number of CRC
screenings in Kentucky, using 75% FIT kits and 25% colonoscopies (Justia,
2011).
About 39% of CRCs are diagnosed at the local stage or confined to the
primary site, but 56% have already spread to regional lymph nodes or have
metastasized. If diagnosed at the localized stage, there is a 90% five-year rel-
ative survival rate, but this decreases to 14% when the cancer is in distant
sites. The survival rate for regional sites is 71% and 35% for unstaged. NCI
(2017a) projects that early detection of CRC could improve survival rates by
about 60%.
KEYWORDS
colorectal cancer screening; human carin ...
Cancer is one of the modern and major causes of mortality worldwide, the incidence and mortality rates vary according to geographical distribution.
It can be controlled by using awareness and screening programs to reduce mortality rates.
Clinical Information Systems in Global Health CareFelix Chisoni
This presentation was specifically meant for novices or those with no background knowledge in technology for healthcare solutions. My aim was to share issues surrounding potential benefits of Clinical Information Systems.It was presented to fellow scholars on 6th April, 2018 at University of Bristol in the United Kingdom.
The presentation begins with a brief history of how cancer epidemiology evolved, and what is the status at present. After describing the burden of the disease of cancer globally and in India, the presentation includes a brief description of Cancer causes and prevention including screening activities. It also talks about the national Cancer Registry Program, NPCDCS and NCCP.
This PDF provides the majority of my slides from the statewide Minnesota Cancer Summit from February 28, 2019. The presentation focuses on Clinical Cancer Advances as published and released by consensus expert panels from The American Society of Clinical Oncology (@ASCO).
Overview of the NIH-funded RADx-UP - Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP) Coordination and Data Collection Center (CDCC) with a focus on the Common Data Elements used to gather data across the RADx-UP Consortium for COVID-19 testing.
RADx-UP CDCC presentation for the NIH Disaster Interest GroupWarren Kibbe
Presentation on the RADx-Underserved Populations Coordination and Data Collection Center with an emphasis on how it will help understand and reduce the disparities associated with the COVDI-19 pandemic
Data Harmonization for a Molecularly Driven Health SystemWarren Kibbe
Maximizing the value of data, computing, data science in an academic medical center, or 'towards a molecularly informed Learning Health System. Given in October at the University of Florida in Gainesville
Data Harmonization for a Molecularly Driven Health SystemWarren Kibbe
Seminar for Dr. Min Zhang's Purdue Bioinformatics Seminar Series. Touched on learning health systems, the Gen3 Data Commons, the NCI Genomic Data Commons, Data Harmonization, FAIR, and open science.
Drivers for data sharing in funding of biomedical research. Importance of data sharing on open science, innovation, reproducibility that is enabled by digital technologies and data science.
Data in precision oncology SAMSI Precision Medicine Meeting mar 2019Warren Kibbe
Talk at the March 14-15 2019 SAMSI Advances in Precision and Personalized Medicine held as part of the Program on Statistical, Mathematical, and Computational Methods for Precision Medicine (PMED) at NCSU, Raleigh, NC
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
SuperComputing 16 HPC Matters Panel on Precision Medicine
1. 1
To develop the scientific
evidence base that will lessen
the burden of cancer in the
United States and around the
world.
NCI Mission
2. 2
Cancer Statistics
In 2016 there will be an estimated
1,700,000 new cancer cases
and
600,000 cancer deaths
- American Cancer Society 2016
Cancer remains the second most common cause of death in the U.S.
- Centers for Disease Control and Prevention 2015
3. 3
Understanding Cancer
Precision medicine will lead to fundamental
understanding of the complex interplay between
genetics, epigenetics, nutrition, environment and clinical
presentation and direct effective, evidence-based
prevention and treatment.
4. 4
(10,000+ patient tumors and increasing)
Courtesy of P. Kuhn (USC)
2006-2015:
A Decade of Illuminating the
Underlying Causes of Primary
Untreated Tumors Omics
Characterization
Cancer is a grand challenge
Biological understanding
Advances in scientific methods
Advances in instrumentation
Advances in technology
Data and computation
Cancer Research and Care generate
detailed data that is critical to
create a learning health system for cancer
Requires:
5. 5
Cancer Moonshot
Precision Medicine Initiative (PMI)
National Strategic Computing Initiative (NSCI)
Making data available: Genomic Data Commons
Using the cloud: NCI Cloud Pilots
Computation and data: DOE-NCI Pilots
Audacious yet possible!
Investigate, explore, predict using real-world data!
7. How do we solve problems in Cancer
Support and incentives for team science, collaboration
We need FAIR, open data
Support open source, open science
Support for rapid innovation
Key message: The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.